Responsible Use of Rifampin for the Treatment of Latent Tuberculosis Infection

Overview

Journal CMAJ

Date 2019 Jun 26

PMID 31235488

Citations 5

Authors

Jane Batt

Kamran Khan

Affiliations

Soon will be listed here.

Citing Articles

Short Combination Treatment for Latent Tuberculosis in Children.

Cho H J Korean Med Sci. 2024; 39(7):e97.

PMID: 38412616 PMC: 10896706. DOI: 10.3346/jkms.2024.39.e97.

Latent Tuberculosis Treatment among Hard-to-Reach Ethiopian Immigrants: Nurse-Managed Directly Observed versus Self-Administered Isoniazid Therapy.

Bishara H, Green M, Saffouri A, Weiler-Ravell D Trop Med Infect Dis. 2023; 8(2).

PMID: 36828539 PMC: 9964860. DOI: 10.3390/tropicalmed8020123.

Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis.

Kendall E, Hussain H, Kunkel A, Kubiak R, Trajman A, Menzies R BMC Med. 2021; 19(1):315.

PMID: 34903214 PMC: 8670249. DOI: 10.1186/s12916-021-02189-w.

No evidence of increased risk of acquired rifampin resistance.

Menzies D, Cook V, Long R, Ruslami R CMAJ. 2019; 191(47):E1314-E1315.

PMID: 31767710 PMC: 6877362. DOI: 10.1503/cmaj.73353.

Responsible use of rifampin in Canada is threatened by irresponsible shortages.

Houston A, Cooper R, Khan F CMAJ. 2019; 191(41):E1139.

PMID: 31615823 PMC: 6791796. DOI: 10.1503/cmaj.73160.

References

Mase S, Ramsay A, Ng V, Henry M, Hopewell P, Cunningham J . Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2007; 11(5):485-95. View

Kik S, Olthof S, de Vries J, Menzies D, Kincler N, van Loenhout-Rooyakkers J . Direct and indirect costs of tuberculosis among immigrant patients in the Netherlands. BMC Public Health. 2009; 9:283. PMC: 2734849. DOI: 10.1186/1471-2458-9-283. View

van Halsema C, Fielding K, Chihota V, Russell E, Lewis J, Churchyard G . Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS. 2010; 24(7):1051-5. DOI: 10.1097/QAD.0b013e32833849df. View

Oni T, Burke R, Tsekela R, Bangani N, Seldon R, Gideon H . High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax. 2011; 66(8):669-73. PMC: 3142344. DOI: 10.1136/thx.2011.160168. View

Gonzalez-Angulo Y, Wiysonge C, Geldenhuys H, Hanekom W, Mahomed H, Hussey G . Sputum induction for the diagnosis of pulmonary tuberculosis: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2011; 31(7):1619-30. DOI: 10.1007/s10096-011-1485-6. View

Sterling T, Villarino M, Borisov A, Shang N, Gordin F, Bliven-Sizemore E . Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011; 365(23):2155-66. DOI: 10.1056/NEJMoa1104875. View

Marks S, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S . Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis. 2014; 20(5):812-21. PMC: 4012799. DOI: 10.3201/eid2005.131037. View

Lonnroth K, Migliori G, Abubakar I, DAmbrosio L, de Vries G, Diel R . Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015; 45(4):928-52. PMC: 4391660. DOI: 10.1183/09031936.00214014. View

Den Boon S, Matteelli A, Getahun H . Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016; 20(8):1065-71. PMC: 5642842. DOI: 10.5588/ijtld.15.0908. View

10.

Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H . Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med. 2018; 379(5):440-453. DOI: 10.1056/NEJMoa1714283. View